The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Revised Response Criteria for Malignant Lymphoma
Open accessAbstract
Purpose: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Methods: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18 F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. Results: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. Conclusion: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationWotherspoon, A. C., Diss, T. C., Pan, L., Isaacson, P. G., Doglioni, C., Moschini, A., & de Boni, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)91409-f · Cited by 2,118
Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2305 · Cited by 1,335
Self-citationAbrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.524 · Cited by 914
Self-citationPositron-Emission Tomography and Assessment of Cancer Therapy
Juweid, M. E., & Cheson, B. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050276 · Cited by 750
Self-citationHutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.-M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2252 · Cited by 726
Self-citationJerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999) · Blood · doi:10.1182/blood.v94.2.429 · Cited by 565
Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J.-D., Belhadj, K., Gaulard, P., Garderet, L., Lepage, E., Reyes, F., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0272 · Cited by 494
Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., Vanuytsel, L., Bormans, G., Balzarini, J., De Wolf-Peeters, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.414 · Cited by 465
Self-citationUtility of FDG-PET scanning in lymphoma by WHO classification
Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J.-A., Zhuang, H., Pitsilos, S., Bagg, A., Downs, L., Mehrotra, A., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2778 · Cited by 437
Cited by
Items 101–183 of 183
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J. F., Kelly, K., Gribben, J., Pfreunschuh, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx097 · Cited by 369
Self-citationRoemer, M. G. M., Redd, R. A., Cader, F. Z., Pak, C. J., Abdelrahman, S., Ouyang, J., Sasse, S., Younes, A., Fanale, M., Santoro, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.3994 · Cited by 364
Low-Intensity Therapy in Adults with Burkitt's Lymphoma
Dunleavy, K., Pittaluga, S., Shovlin, M., Steinberg, S. M., Cole, D., Grant, C., Widemann, B., Staudt, L. M., Jaffe, E. S., Little, R. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1308392 · Cited by 360
Nowakowski, G. S., LaPlant, B., Macon, W. R., Reeder, C. B., Foran, J. M., Nelson, G. D., Thompson, C. A., Rivera, C. E., Inwards, D. J., Micallef, I. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5714 · Cited by 359
Self-citationGeoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30671-0 · Cited by 357
Non-Hodgkin Lymphoma: Diagnosis and Treatment
Ansell, S. M., & Armitage, J. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1087 · Cited by 356
Ansell, S. M., Minnema, M. C., Johnson, P., Timmerman, J. M., Armand, P., Shipp, M. A., Rodig, S. J., Ligon, A. H., Roemer, M. G. M., Reddy, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00766 · Cited by 353
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O’Connor, O. A., Siddiqi, T., Kennedy, D. A., & Oki, Y. (2014) · Blood · doi:10.1182/blood-2013-12-542142 · Cited by 352
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
Ben-Haim, S., & Ell, P. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054205 · Cited by 351
Sehn, L. H., Chua, N., Mayer, J., Dueck, G., Trněný, M., Bouabdallah, K., Fowler, N., Delwail, V., Press, O., Salles, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30097-3 · Cited by 349
Self-citationOverall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
Ansell, S. M., Radford, J., Connors, J. M., Długosz-Danecka, M., Kim, W.-S., Gallamini, A., Ramchandren, R., Friedberg, J. W., Advani, R., Hutchings, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206125 · Cited by 347
Self-citationClonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Ahn, I. E., Underbayev, C., Albitar, A., Herman, S. E. M., Tian, X., Maric, I., Arthur, D. C., Wake, L., Pittaluga, S., Yuan, C. M., et al. (2017) · Blood · doi:10.1182/blood-2016-06-719294 · Cited by 341
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Flinn, I. W., Hillmen, P., Montillo, M., Nagy, Z., Illés, Á., Etienne, G., Delgado, J., Kuss, B. J., Tam, C. S., Gasztonyi, Z., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850461 · Cited by 341
Rothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614636 · Cited by 337
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., Takahashi, K., Glover, C., Keane, C., Kihira, S., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635169 · Cited by 337
Palanca-Wessels, M. C. A., Czuczman, M., Salles, G., Assouline, S., Sehn, L. H., Flinn, I., Patel, M. R., Sangha, R., Hagenbeek, A., Advani, R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70128-2 · Cited by 336
Self-citationSeto, W.-K., Chan, T. S. Y., Hwang, Y.-Y., Wong, D. K.-H., Fung, J., Liu, K. S.-H., Gill, H., Lam, Y.-F., Lie, A. K. W., Lai, C.-L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7081 · Cited by 332
Wang, C.-M., Wu, Z.-Q., Wang, Y., Guo, Y.-L., Dai, H.-R., Wang, X.-H., Li, X., Zhang, Y.-J., Zhang, W.-Y., Chen, M.-X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1365 · Cited by 332
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Chen, R., Zinzani, P. L., Lee, H. J., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., et al. (2019) · Blood · doi:10.1182/blood.2019000324 · Cited by 331
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., Fayad, L., Forero, A., Glenn, M. J., Gockerman, J. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0021 · Cited by 329
Self-citationPlathow, C., & Weber, W. A. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045930 · Cited by 328
Moskowitz, C. H., Schöder, H., Teruya-Feldstein, J., Sima, C., Iasonos, A., Portlock, C. S., Straus, D., Noy, A., Palomba, M. L., O'Connor, O. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5942 · Cited by 326
Meignan, M., Cottereau, A. S., Versari, A., Chartier, L., Dupuis, J., Boussetta, S., Grassi, I., Casasnovas, R.-O., Haioun, C., Tilly, H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9440 · Cited by 326
Self-citationInfante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1248 · Cited by 317
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Biggi, A., Gallamini, A., Chauvie, S., Hutchings, M., Kostakoglu, L., Gregianin, M., Meignan, M., Malkowski, B., Hofman, M. S., & Barrington, S. F. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.110890 · Cited by 311
Brudno, J. N., Lam, N., Vanasse, D., Shen, Y.-W., Rose, J. J., Rossi, J., Xue, A., Bot, A., Scholler, N., Mikkilineni, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0737-3 · Cited by 311
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Cappell, K. M., Sherry, R. M., Yang, J. C., Goff, S. L., Vanasse, D. A., McIntyre, L., Rosenberg, S. A., & Kochenderfer, J. N. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01467 · Cited by 311
Hernandez‐Ilizaliturri, F. J., Deeb, G., Zinzani, P. L., Pileri, S. A., Malik, F., Macon, W. R., Goy, A., Witzig, T. E., & Czuczman, M. S. (2011) · Cancer · doi:10.1002/cncr.26135 · Cited by 304
The role of FDG-PET scans in patients with lymphoma
Seam, P., Juweid, M. E., & Cheson, B. D. (2007) · Blood · doi:10.1182/blood-2007-06-097238 · Cited by 304
Self-citationMcCurdy, S. R., Kanakry, J. A., Showel, M. M., Tsai, H.-L., Bolaños-Meade, J., Rosner, G. L., Kanakry, C. G., Perica, K., Symons, H. J., Brodsky, R. A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-623991 · Cited by 303
Budde, L. E., Assouline, S., Sehn, L. H., Schuster, S. J., Yoon, S.-S., Yoon, D. H., Matasar, M. J., Bosch, F., Kim, W. S., Nastoupil, L. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.00931 · Cited by 302
Jacobsen, E. D., Sharman, J. P., Oki, Y., Advani, R. H., Winter, J. N., Bello, C. M., Spitzer, G., Palanca-Wessels, M. C., Kennedy, D. A., Levine, P., et al. (2015) · Blood · doi:10.1182/blood-2014-09-598763 · Cited by 300
Ramos, C. A., Rouce, R., Robertson, C. S., Reyna, A., Narala, N., Vyas, G., Mehta, B., Zhang, H., Dakhova, O., Carrum, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.009 · Cited by 299
Delanoy, N., Michot, J.-M., Comont, T., Kramkimel, N., Lazarovici, J., Dupont, R., Champiat, S., Chahine, C., Robert, C., Herbaux, C., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30175-3 · Cited by 299
Evaluation of lymph nodes with RECIST 1.1
Schwartz, L. H., Bogaerts, J., Ford, R., Shankar, L., Therasse, P., Gwyther, S., & Eisenhauer, E. A. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.028 · Cited by 298
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Noy, A., de Vos, S., Thieblemont, C., Martin, P., Flowers, C. R., Morschhauser, F., Collins, G. P., Ma, S., Coleman, M., Peles, S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-747345 · Cited by 298
Loken, M. R., Alonzo, T. A., Pardo, L., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Ho, P. A., Franklin, J., Cooper, T. M., Gamis, A. S., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408336 · Cited by 297
El-Galaly, T. C., d'Amore, F., Mylam, K. J., de Nully Brown, P., Bøgsted, M., Bukh, A., Specht, L., Loft, A., Iyer, V., Hjorthaug, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.4036 · Cited by 295
Self-citationHorwitz, S. M., Koch, R., Porcu, P., Oki, Y., Moskowitz, A., Perez, M., Myskowski, P., Officer, A., Jaffe, J. D., Morrow, S. N., et al. (2018) · Blood · doi:10.1182/blood-2017-08-802470 · Cited by 290
Zinzani, P. L., Ribrag, V., Moskowitz, C. H., Michot, J.-M., Kuruvilla, J., Balakumaran, A., Zhang, Y., Chlosta, S., Shipp, M. A., & Armand, P. (2017) · Blood · doi:10.1182/blood-2016-12-758383 · Cited by 289
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Yang, J. C., Sherry, R. M., Feldman, S. A., McIntyre, L., Bot, A., Rossi, J., Lam, N., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.004 · Cited by 284
Vail, D. M., Michels, G. M., Khanna, C., Selting, K. A., London, C. A., & Veterinary Cooperative Oncology Group (2010) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2009.00200.x · Cited by 281
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
Barrington, S. F., & Kluge, R. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3690-8 · Cited by 281
Role of Functional Imaging in the Management of Lymphoma
Cheson, B. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5225 · Cited by 280
Self-citationResponse Criteria in Oncologic Imaging: Review of Traditional and New Criteria
Tirkes, T., Hollar, M. A., Tann, M., Kohli, M. D., Akisik, F., & Sandrasegaran, K. (2013) · RadioGraphics · doi:10.1148/rg.335125214 · Cited by 279
Kanakry, C. G., O'Donnell, P. V., Furlong, T., de Lima, M. J., Wei, W., Medeot, M., Mielcarek, M., Champlin, R. E., Jones, R. J., Thall, P. F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0625 · Cited by 278
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Ramos, C. A., Savoldo, B., Torrano, V., Ballard, B., Zhang, H., Dakhova, O., Liu, E., Carrum, G., Kamble, R. T., Gee, A. P., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86000 · Cited by 276
Nowakowski, G. S., Chiappella, A., Gascoyne, R. D., Scott, D. W., Zhang, Q., Jurczak, W., Özcan, M., Hong, X., Zhu, J., Jin, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01366 · Cited by 275
Self-citationDistinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Haradhvala, N. J., Leick, M. B., Maurer, K., Gohil, S. H., Larson, R. C., Yao, N., Gallagher, K. M. E., Katsis, K., Frigault, M. J., Southard, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01959-0 · Cited by 271
Kuruvilla, J., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N. A., Fogliatto, L. M., Goncalves, I., de Oliveira, J. S. R., Buccheri, V., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00005-x · Cited by 269
Assessing Tumor Response to Therapy
Weber, W. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057174 · Cited by 269
Brown, J. R., Moslehi, J., O’Brien, S., Ghia, P., Hillmen, P., Cymbalista, F., Shanafelt, T. D., Fraser, G., Rule, S., Kipps, T. J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.171041 · Cited by 267
Self-citationPress, O. W., Li, H., Schöder, H., Straus, D. J., Moskowitz, C. H., LeBlanc, M., Rimsza, L. M., Bartlett, N. L., Evens, A. M., Mittra, E. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1119 · Cited by 267
Self-citationVidal, L., Gafter-Gvili, A., Leibovici, L., Dreyling, M., Ghielmini, M., Hsu Schmitz, S.-F., Cohen, A., & Shpilberg, O. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn478 · Cited by 266
Self-citationFederico, M., Luminari, S., Dondi, A., Tucci, A., Vitolo, U., Rigacci, L., Di Raimondo, F., Carella, A. M., Pulsoni, A., Merli, F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0866 · Cited by 264
Self-citationFlinn, I. W., Miller, C. B., Ardeshna, K. M., Tetreault, S., Assouline, S. E., Mayer, J., Merli, M., Lunin, S. D., Pettitt, A. R., Nagy, Z., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00915 · Cited by 264
Younes, A., Sureda, A., Ben-Yehuda, D., Zinzani, P. L., Ong, T.-C., Prince, H. M., Harrison, S. J., Kirschbaum, M., Johnston, P., Gallagher, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1350 · Cited by 263
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
Armand, P., Rodig, S., Melnichenko, V., Thieblemont, C., Bouabdallah, K., Tumyan, G., Özcan, M., Portino, S., Fogliatto, L., Caballero, M. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01389 · Cited by 262
Itti, E., Meignan, M., Berriolo-Riedinger, A., Biggi, A., Cashen, A. F., Véra, P., Tilly, H., Siegel, B. A., Gallamini, A., Casasnovas, R.-O., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2435-6 · Cited by 255
Bannerji, R., Arnason, J. E., Advani, R. H., Brown, J. R., Allan, J. N., Ansell, S. M., Barnes, J. A., O'Brien, S. M., Chávez, J. C., Duell, J., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00072-2 · Cited by 254
Younes, A., Thieblemont, C., Morschhauser, F., Flinn, I., Friedberg, J. W., Amorim, S., Hivert, B., Westin, J., Vermeulen, J., Bandyopadhyay, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70311-0 · Cited by 254
Kahl, B. S., Spurgeon, S. E., Furman, R. R., Flinn, I. W., Coutre, S. E., Brown, J. R., Benson, D. M., Byrd, J. C., Peterman, S., Cho, Y., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537555 · Cited by 252
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
Ruan, J., Martin, P., Shah, B., Schuster, S. J., Smith, S. M., Furman, R. R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505237 · Cited by 236
Geoerger, B., Zwaan, C. M., Marshall, L. V., Michon, J., Bourdeaut, F., Casanova, M., Corradini, N., Rossato, G., Farid-Kapadia, M., Shemesh, C. S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30693-x · Cited by 171
Ohmachi, K., Niitsu, N., Uchida, T., Kim, S. J., Ando, K., Takahashi, N., Takahashi, N., Uike, N., Eom, H. S., Chae, Y. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5203 · Cited by 171
Self-citationFeasibility of state of the art PET/CT systems performance harmonisation
Kaalep, A., Sera, T., Rijnsdorp, S., Yaqub, M., Talsma, A., Lodge, M. A., & Boellaard, R. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3977-4 · Cited by 160
Fajgenbaum, D. C., Langan, R.-A., Japp, A. S., Partridge, H. L., Pierson, S. K., Singh, A., Arenas, D. J., Ruth, J. R., Nabel, C. S., Stone, K., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126091 · Cited by 147
Spencer, A., Yoon, S.-S., Harrison, S. J., Morris, S. R., Smith, D. A., Brigandi, R. A., Gauvin, J., Kumar, R., Opalinska, J. B., & Chen, C. (2014) · Blood · doi:10.1182/blood-2014-03-559963 · Cited by 142
Porrata, L. F., Ristow, K., Habermann, T., Inwards, D. J., Micallef, I. N., & Markovic, S. N. (2010) · American Journal of Hematology · doi:10.1002/ajh.21849 · Cited by 124
Davies, A., Merli, F., Mihaljević, B., Mercadal, S., Siritanaratkul, N., Solal-Céligny, P., Boehnke, A., Berge, C., Genevray, M., Zharkov, A., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30078-9 · Cited by 125
Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology
Ziai, P., Hayeri, M. R., Salei, A., Salavati, A., Houshmand, S., Alavi, A., & Teytelboym, O. M. (2016) · RadioGraphics · doi:10.1148/rg.2016150102 · Cited by 106
Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Dietrich, S., et al. (2025) · Blood · doi:10.1182/blood.2024025454 · Cited by 94
Carpio, C., Bouabdallah, R., Ysebaert, L., Sancho, J.-M., Salles, G., Cordoba, R., Pinto, A., Gharibo, M., Rasco, D., Panizo, C., et al. (2020) · Blood · doi:10.1182/blood.2019002395 · Cited by 72
Kunou, S., Shimada, K., Takai, M., Sakamoto, A., Aoki, T., Hikita, T., Kagaya, Y., Iwamoto, E., Sanada, M., Shimada, S., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01829-y · Cited by 62
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
Batlevi, C. L., Kasamon, Y., Bociek, R. G., Lee, P., Gore, L., Copeland, A., Sorensen, R., Ordentlich, P., Cruickshank, S., Kunkel, L., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.142406 · Cited by 59
Dasatinib is an effective treatment for angioimmunoblastic t-cell lymphoma
Nguyen, T. B., Sakata-Yanagimoto, M., Fujisawa, M., Nuhat, S. T., Miyoshi, H., Nannya, Y., Hashimoto, K., Fukumoto, K., Bernard, O. A., Kiyoki, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2787 · Cited by 56
FDG PET/CT-based response assessment in malignancies
Parihar, A. S., Dehdashti, F., & Wahl, R. L. (2023) · RadioGraphics · doi:10.1148/rg.220122 · Cited by 53
“FDG PET was included in the 2007 International Harmonization Project (IHP) criteria for assessing response in HL and NHL (31,32), which recommended visual interpretation of the PET images and comparison of the lesion avidity with the mediastinal blood pool avidity to determine response.”
van Rhee, F., Rosenthal, A., Kanhai, K., Martin, R., Nishimura, K., Hoering, A., & Fajgenbaum, D. C. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007112 · Cited by 48
Ferreri, A. J. M., Sassone, M., Zaja, F., Re, A., Spina, M., Rocco, A. D., Fabbri, A., Stelitano, C., Frezzato, M., Rusconi, C., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30016-9 · Cited by 32
Siddiqi, T., Frankel, P., Beumer, J. H., Kiesel, B. F., Christner, S., Ruel, C., Song, J. Y., Chen, R., Kelly, K. R., Ailawadhi, S., et al. (2020) · Leukemia & Lymphoma · doi:10.1080/10428194.2019.1672052 · Cited by 30
Hude, I., Sasse, S., Bröckelmann, P. J., von Tresckow, B., Momotow, J., Engert, A., & Borchmann, S. (2018) · British Journal of Haematology · doi:10.1111/bjh.14705 · Cited by 27
Ceriani, L., Barrington, S., Biggi, A., Malkowski, B., Metser, U., Versari, A., Martelli, M., Davies, A., Johnson, P. W., Zucca, E., et al. (2017) · Hematological Oncology · doi:10.1002/hon.2339 · Cited by 26
Self-citation
Metadata
- Authors
- Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., Rosen, S. T., Stroobants, S., Lister, T. A., Hoppe, R. T., Dreyling, M., Tobinai, K., Vose, J. M., Connors, J. M., Federico, M., & Diehl, V.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-02-10
- Volume
- 25
- Issue
- 5
- Pages
- 579-586
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2133201432
- Cited by
- 4,426
- References
- 36
- FWCI
- 108.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.